A significant increase in life expectancy in successive birth cohorts of people with cystic
fibrosis (CF) is a result of more effective treatment for the disease. It is also now widely …

Background The reduction of lung inflammation is one of the goals of cystic fibrosis therapy.
Inhaled corticosteroids are often used in this respect to treat children and adults with cystic …

The incidence of empyema complicating community‐acquired pneumonia is increasing and
causes significant childhood morbidity. Pneumococcal infection remains the most common …

Background The macrolide antibiotic azithromycin has anti-inflammatory properties potentially
beneficial in cystic fibrosis. Since findings of open pilot studies seemed to show clinical …

This guideline has assessed available evidence and attempted to gauge consensus opinion
where evidence is unavailable. The lack of paediatric data, in particular from randomised …

Background Lumacaftor and ivacaftor combination treatment showed efficacy in patients
aged 12 years or older with cystic fibrosis homozygous for F508del-cystic fibrosis …

Nitric oxide (NO) produced within the respiratory tract is detectable in exhaled and nasal air.
Its synthesis may be induced by inflammatory cytokines and reduced by glucocorticoids. …

INTRODUCTION Need for new recommendations for managing passengers with respiratory
disease planning air travel Since the first British Thoracic Society (BTS) recommendations …

Background: The role of intrapleural fibrinolytic agents in the treatment of childhood
empyema has not been established. A randomised double blind placebo controlled trial of …

Accepted 8 April 2009 ‘‘… as we know, there are known knowns; there are things we know
we know. We also know there are known unknowns; that is to say we know there are some …